World's Best Scientists 2026 revealed!
Dominick J. Angiolillo

Dominick J. Angiolillo

D-Index & Metrics

Medicine

D-Index
122
Citations
61369
World Ranking
3447
National Ranking
1895

Overview

Dominick J. Angiolillo is affiliated with the University of Florida in the United States and has contributed extensively to medical research, particularly in cardiology and cardiovascular medicine. Their body of work encompasses a wide range of topics within the field of medicine, with a strong focus on antiplatelet therapy and cardiovascular diseases.

They have authored or co-authored research papers, including notable recent publications such as:

  • 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, 2020, European Heart Journal
  • The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease, 2020, Thrombosis and Haemostasis
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention, 2021, Circulation
  • Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19, 2021, JAMA
  • P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials, 2021, BMJ

Their research spans several main fields and subfields, with over a thousand medical publications. Specifically, the subfields include cardiology and cardiovascular medicine, surgery, internal medicine, endocrinology, diabetes and metabolism, and radiology, nuclear medicine and imaging.

Dominick J. Angiolillo's research focuses on topics such as:

  • Antiplatelet Therapy and Cardiovascular Diseases
  • Acute Myocardial Infarction Research
  • Coronary Interventions and Diagnostics
  • Atrial Fibrillation Management and Outcomes
  • Venous Thromboembolism Diagnosis and Management
  • Lipoproteins and Cardiovascular Health
  • Diabetes Treatment and Management

The researcher has collaborated frequently with other scholars in their field. Regular co-authors include Roxana Mehran, Mattía Galli, Davide Capodanno, Francesco Franchi, and Deepak L. Bhatt.

Dominick J. Angiolillo's work has been published predominantly in leading cardiovascular journals, including:

  • Journal of the American College of Cardiology
  • JACC: Cardiovascular Interventions
  • European Heart Journal
  • European Heart Journal - Cardiovascular Pharmacotherapy
  • Circulation

In addition to articles, Dominick J. Angiolillo has contributed to the field through book publications, with titles such as Precision Medicine for Antithrombotic Therapy in Patients after Percutaneous Coronary Interventions, published by Frontiers Media in 2023.

Best Publications

  • Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

    Matthew J. Price;Peter B. Berger;Paul S. Teirstein;Jean-François Tanguay

  • Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention

    Matthew J. Price;Peter B. Berger;Paul S. Teirstein;Dominick J. Angiolillo

  • Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate

    Laurent Bonello;Udaya S. Tantry;Rossella Marcucci;Ruediger Blindt

  • Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention : A Consensus Document From the Academic Research Consortium for High Bleeding Risk

    Philip Urban;Roxana Mehran;Roisin Colleran;Dominick J. Angiolillo

  • Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

    Stephen D. Wiviott;Dietmar Trenk;Andrew L. Frelinger;Michelle O’Donoghue

  • Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives

    Dominick J. Angiolillo;Antonio Fernandez-Ortiz;Esther Bernardo;Fernando Alfonso

  • Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

    Stephen D. Wiviott;Eugene Braunwald;Dominick J. Angiolillo;Simha Meisel

  • Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding

    Udaya S. Tantry;Laurent Bonello;Daniel Aradi;Matthew J. Price

  • Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

    Deepak L. Bhatt;Gregg W. Stone;Kenneth W. Mahaffey;C. Michael Gibson

  • Ticagrelor with or without Aspirin in High-Risk Patients after PCI

    Roxana Mehran;Usman Baber;Samin K Sharma;David J Cohen

  • A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.

    Dietmar Trenk;Gregg W. Stone;Meinrad Gawaz;Adnan Kastrati

  • Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.

    Raúl Moreno;Cristina Fernández;Rosana Hernández;Fernando Alfonso

  • Platelet Inhibition with Cangrelor in Patients Undergoing PCI

    Robert A. Harrington;Gregg W. Stone;Steven McNulty;Harvey D. White

  • Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.

    Stefanie Schüpke;Franz-Josef Neumann;Maurizio Menichelli;Katharina Mayer

  • Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.

    Dominick J. Angiolillo;Steven B. Shoemaker;Bhaloo Desai;Hang Yuan

  • Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment

    Dominick J. Angiolillo;Antonio Fernandez-Ortiz;Esther Bernardo;Celia Ramírez

  • Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

    Dominick J. Angiolillo;Michael S. Firstenberg;Matthew J. Price;Pradyumna E. Tummala

  • Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial

    Manel Sabaté;Pilar Jiménez-Quevedo;Dominick J. Angiolillo;Joan Antoni Gómez-Hospital

  • Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.

    Matthew J. Price;Dominick J. Angiolillo;Paul S. Teirstein;Elizabeth Lillie

  • A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity

    D Trenk;GW Stone;M Gawaz;A Kastrati

Frequent Co-Authors

Davide Capodanno
Davide Capodanno University of Catania
Deepak L. Bhatt
Deepak L. Bhatt Mount Sinai Hospital
Carlos Macaya
Carlos Macaya Complutense University of Madrid
Fernando Alfonso
Fernando Alfonso Hospital Universitario de La Princesa
Manel Sabaté
Manel Sabaté University of Barcelona
Javier Escaned
Javier Escaned Hospital Clínico San Carlos
Roxana Mehran
Roxana Mehran Icahn School of Medicine at Mount Sinai
Paul A. Gurbel
Paul A. Gurbel Inova Fairfax Hospital
Robert F. Storey
Robert F. Storey University of Sheffield
Marco Valgimigli
Marco Valgimigli University of Bern

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, there are flexible online degree options that can open new career pathways in healthcare. One common concern is cost—if you’re wondering how much is online nursing school, you'll find that tuition can vary widely. Many programs cater to working adults and offer affordable options.

Registered nurses looking to advance their education often pursue bridge programs. If this is you, researching rn to bsn online cost is important, since tuition may differ based on state, transfer credits, and program length.

For those considering leadership roles or academia, online phd programs nursing offer a convenient path to a terminal degree that fits around professional responsibilities. Meanwhile, career changers without a nursing background may be interested in online msn programs for non nurses, which provide an accelerated path to advanced practice nursing.

Online healthcare degrees can accommodate different career goals, experience levels, and budgets—making medical careers more accessible than ever.

Best Scientists Citing Dominick J. Angiolillo

Trending Scientists

Recently Published Articles